Q-omics provides the consensus-scored TTC27 profile across patient tissues and cancer cell-line models. TTC27 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC27 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TTC27 protein abundance shows 23,163 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where TTC27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC27 survival associations across molecular data types. TTC27 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC27 RNA expression–survival associations across cancer types. High TTC27 expression shows unfavorable associations in KIRP, LIHC, MESO and ACC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC27 RNA expression.
This table summarizes TTC27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC27 shows higher tumor expression in KIRC, LIHC, COAD, LUAD, LUSC and STAD. The KIRC box plot shows higher TTC27 RNA expression in tumor versus normal tissue (log2 FC = +0.549, t-test p < 0.001).
This table shows molecular features associated with TTC27 in patient tissues and cancer cell lines. In patient samples, TTC27 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
